Ascentage pharma presents results from five preclinical studies at 2025 american association of cancer research (aacr) annual meeting, highlighting strong synergistic effects of olverembatinib combined with lisaftoclax

Rockville, md. and suzhou, china, april 28, 2025 (globe newswire) -- ascentage pharma (nasdaq: aapg; hkex: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that it has presented results from five preclinical studies during poster presentations at the 2025 american association for cancer research (aacr) annual meeting, taking place april 25-30, 2025, in chicago, illinois, usa.
AAPG Ratings Summary
AAPG Quant Ranking